Silence Therapeutics (SLN) analyst forecast and price target
Analyst forecast
Consensus of 7 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Morgan Stanley | Maintained | Overweight | $32.00 from $25.00 | Aug 11, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Jun 24, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $75.00 | Jun 17, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $75.00 | Mar 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $75.00 | Sep 16, 2025 |
| Chardan Capital | Maintained | Buy | $35.00 | Aug 8, 2025 |
| Chardan Capital | Maintained | Buy | $35.00 | Jun 13, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $75.00 | Jun 13, 2025 |
| Chardan Capital | Maintained | Buy | $35.00 from $55.00 | May 9, 2025 |
| Morgan Stanley | Maintained | Overweight | $25.00 from $45.00 | May 9, 2025 |
| Goldman Sachs | Maintained | Sell | $3.00 from $4.00 | May 9, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $75.00 | Mar 7, 2025 |
| Morgan Stanley | Maintained | Overweight | $45.00 from $49.00 | Mar 5, 2025 |
| Goldman Sachs | Maintained | Sell | $4.00 from $6.00 | Mar 4, 2025 |
| BMO Capital | Maintained | Outperform | $25.00 from $67.00 | Mar 4, 2025 |
| Goldman Sachs | Initiated Coverage | Sell | $6.00 | Feb 11, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $75.00 | Feb 3, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $75.00 | Jan 29, 2025 |
| Chardan Capital | Maintained | Buy | $55.00 | Dec 10, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $75.00 | Dec 9, 2024 |
Frequently asked questions
Is SLN a buy, sell, or hold?
Analysts covering Silence Therapeutics currently average a Buy rating: 6 buy, 0 hold and 1 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on SLN?
On Aug 11, 2026, Morgan Stanley maintained Silence Therapeutics at Overweight with a price target of $32.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.